Blueprint Medicines (NASDAQ:BPMC)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research note issued on Wednesday. They currently have a price objective on the biotechnology company’s stock, down from their prior price objective of .

A number of other equities research analysts have also recently weighed in on the stock. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research note on Monday, September 30th. BidaskClub upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Wednesday, December 18th. Leerink Swann lifted their price objective on shares of Blueprint Medicines from to in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating on shares of Blueprint Medicines in a research note on Thursday, January 9th. Finally, Piper Jaffray Companies dropped their price target on shares of Blueprint Medicines from $85.00 to $77.00 and set a “neutral” rating on the stock in a research report on Friday, December 20th. One analyst has rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $106.25.

Shares of NASDAQ BPMC traded up $3.49 during midday trading on Wednesday, reaching $80.26. 39,660 shares of the company traded hands, compared to its average volume of 782,864. Blueprint Medicines has a 52 week low of $62.82 and a 52 week high of $102.98. The stock has a 50-day moving average price of $78.72 and a 200 day moving average price of $81.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.46 and a quick ratio of 5.46. The company has a market cap of $3.78 billion, a price-to-earnings ratio of -14.89 and a beta of 1.62.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.19) by $0.26. Blueprint Medicines had a negative net margin of 2,258.84% and a negative return on equity of 77.27%. The business had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $2.85 million. During the same period in the previous year, the business earned ($1.66) earnings per share. The company’s revenue was up 734.6% on a year-over-year basis. As a group, analysts expect that Blueprint Medicines will post -7.51 EPS for the current year.

In related news, CEO Jeffrey W. Albers sold 11,744 shares of Blueprint Medicines stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $74.56, for a total value of $875,632.64. Following the transaction, the chief executive officer now owns 66,961 shares of the company’s stock, valued at approximately $4,992,612.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 415 shares of Blueprint Medicines stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $75.00, for a total value of $31,125.00. Following the completion of the transaction, the insider now directly owns 415 shares in the company, valued at approximately $31,125. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,658 shares of company stock worth $2,785,565. 4.02% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BPMC. Ladenburg Thalmann Financial Services Inc. increased its stake in Blueprint Medicines by 62.8% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,097 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 423 shares in the last quarter. Whittier Trust Co. grew its stake in Blueprint Medicines by 58.1% during the 3rd quarter. Whittier Trust Co. now owns 1,632 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Blueprint Medicines by 21.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,906 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 521 shares in the last quarter. Virtu Financial LLC purchased a new position in Blueprint Medicines during the 3rd quarter valued at about $244,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its stake in Blueprint Medicines by 40.4% during the 2nd quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,710 shares of the biotechnology company’s stock valued at $256,000 after acquiring an additional 780 shares in the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Recommended Story: Technical Indicators – What is a Golden Cross?

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.